The assessment of circulating tumor DNA associated with Wnt/β-catenin signaling pathway as a diagnostic tool for liver cancer: a systematic review and meta-analysis

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Davila JA, Duan Z, McGlynn KA, et al. Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States. J Clin Gastroenterol. 2012;46(1):71–77. doi: 10.1097/MCG.0b013e318224d669
   PubMed Web of Science ®Google Scholar
• Tabrizian P, Jibara G, Shrager B, et al. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2015;261(5):947–955. doi: 10.1097/SLA.0000000000000710
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. doi: 10.3322/caac.20138
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi: 10.1016/S0140-6736(18)30010-2
   PubMed Web of Science ®Google Scholar
• Ayuso C, Rimola J, Vilana R, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol. 2018;101:72–81. doi: 10.1016/j.ejrad.2018.01.025
   PubMed Web of Science ®Google Scholar
• Yin XY, Lu MD. Percutaneous ablation for small hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2009;3(2):121–130. doi: 10.1586/egh.09.7
   PubMedGoogle Scholar
• Liu S, Wang M, Zheng C, et al. Diagnostic value of serum glypican-3 alone and in combination with AFP as an aid in the diagnosis of liver cancer. Clin Biochem. 2020;79:54–60. doi: 10.1016/j.clinbiochem.2020.02.009
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chen P, Xie H, et al. Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: a systematic review and meta-analysis. Cancer Med. 2020;9(4):1349–1364. doi: 10.1002/cam4.2799
   PubMed Web of Science ®Google Scholar
• Labgaa I, Villacorta-Martin C, D’Avola D, et al. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene. 2018;37(27):3740–3752. doi: 10.1038/s41388-018-0206-3
   PubMed Web of Science ®Google Scholar
• Chabon JJ, Simmons AD, Lovejoy AF, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016;7(1):11815. doi: 10.1038/ncomms11815
   PubMed Web of Science ®Google Scholar
• Wu X, Li J, Gassa A, et al. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma. Int J Biol Sci. 2020;16(9):1551–1562. doi: 10.7150/ijbs.44024
   PubMed Web of Science ®Google Scholar
• Li YH, Yang SL, Zhang GF, et al. Mefloquine targets β-catenin pathway and thus can play a role in the treatment of liver cancer. Microb Pathog. 2018;118:357–360. doi: 10.1016/j.micpath.2018.03.042
   PubMed Web of Science ®Google Scholar
• Liu J, Xiao Q, Xiao J, et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7(1):3. doi: 10.1038/s41392-021-00762-6
   PubMed Web of Science ®Google Scholar
• Quan H, Zhou F, Nie D, et al. Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition. Oncogene. 2014;33(22):2826–2835. doi: 10.1038/onc.2013.225
   PubMed Web of Science ®Google Scholar
• Cieply B, Zeng G, Proverbs-Singh T, et al. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology. 2009;49(3):821–831. doi: 10.1002/hep.22695
   PubMed Web of Science ®Google Scholar
• Huang ZH, Hu Y, Hua D, et al. Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma. Exp Mol Pathol. 2011;91(3):702–707. doi: 10.1016/j.yexmp.2011.08.004
   PubMed Web of Science ®Google Scholar
• Iizuka N, Oka M, Sakaida I, et al. Efficient detection of hepatocellular carcinoma by a hybrid blood test of epigenetic and classical protein markers. Clin Chim Acta. 2011;412(1–2):152–158. doi: 10.1016/j.cca.2010.09.028
   PubMed Web of Science ®Google Scholar
• McGrath TA, Alabousi M, Skidmore B, et al. Recommendations for reporting of systematic reviews and meta-analyses of diagnostic test accuracy: a systematic review. Syst Rev. 2017;6(1):6. doi: 10.1186/s13643-017-0590-8
   PubMedGoogle Scholar
• Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–536. doi: 10.7326/0003-4819-155-8-201110180-00009
   PubMed Web of Science ®Google Scholar
• Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005;58(9):882–893. doi: 10.1016/j.jclinepi.2005.01.016
   PubMed Web of Science ®Google Scholar
• Lu HY, Lin L, Liu JB. Clinical significance of CpG island methylator Phenotype(CIMP) in plasma associated with prognosis in hepatocellular carcinoma. J Mod Lab Med. 2013;28(6):22–25.
   Google Scholar
• Wang F, Hua D, Wu YY, et al. The clinical significance of plasma methylation analysis of GSTP1 and SFRP1 for early detection of hepatocellular carcinoma. Chin Oncol. 2011;21(1):12–16.
   Google Scholar
• Hu Y, Hua D, Cheng ZH, et al. Clinical value of methylation of plasma adenomatous polyposis coli gene in the molecular diagnosis of hepatocellular carcinoma. Tumor. 2011;31(10):924–929.
   Google Scholar
• Liu JB, Zhang YX, Zhou SH, et al. CpG island methylator phenotype in plasma is associated with hepatocellular carcinoma prognosis. World J Gastroenterol. 2011;17(42):4718–4724. doi: 10.3748/wjg.v17.i42.4718
   PubMed Web of Science ®Google Scholar
• Dong X, Hou Q, Chen Y, et al. Diagnostic value of the methylation of multiple gene promoters in serum in hepatitis B virus-related hepatocellular carcinoma. Dis Markers. 2017;2017:2929381. doi: 10.1155/2017/2929381
   PubMed Web of Science ®Google Scholar
• Huang Y, Wei L, Sun A-M, et al. The evaluation value of methylation status of CpG island of SFRP1 and LINE1 gene promoter area in the prognosis of hepatocellular carcinoma. J Sichuan Univ (Med Sci Edi). 2016;47(6):883–888.
   Google Scholar
• Liu Y, Liu F, Shen F, et al. Expression and clinical significance of WIF-1 DNA methylation in hepatic cancer. J Clin Pathol Res. 2015;35(11):1943–1947.
   Google Scholar
• Liu HH, Fang Y, Wang JW, et al. Hypomethylation of the cyclin D1 promoter in hepatitis B virus-associated hepatocellular carcinoma. Medicine (Baltimore). 2020;99(20):e20326. doi: 10.1097/MD.0000000000020326
   PubMed Web of Science ®Google Scholar
• Chang H, Yi B, Li L, et al. Methylation of tumor associated genes in tissue and plasma samples from liver disease patients. Exp Mol Pathol. 2008;85(2):96–100. doi: 10.1016/j.yexmp.2008.07.001
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang B, Wang Y, et al. Methylation profile of tumor suppressor genes in the cell-free DNA of plasma in hepatocellular carcinoma. Chin J Clin Oncol. 2013;40(23):1436–1440.
   Google Scholar
• Kumar S, Nadda N, Quadri A, et al. Assessments of TP53 and CTNNB1 gene hotspot mutations in circulating tumour DNA of hepatitis B virus-induced hepatocellular carcinoma. Front Genet. 2023;14:1235260. doi: 10.3389/fgene.2023.1235260
   PubMed Web of Science ®Google Scholar
• Lin D, Luo R, Ye Z, et al. Genomic characterization of early-stage hepatocellular carcinoma patients with hepatitis B using circulating tumor DNA. Clin Res Hepatol Gastroenterol. 2023;47(7):102161. doi: 10.1016/j.clinre.2023.102161
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi: 10.1038/s41575-019-0186-y
   PubMed Web of Science ®Google Scholar
• Murtaza M, Dawson SJ, Tsui DW, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497(7447):108–112. doi: 10.1038/nature12065
   PubMed Web of Science ®Google Scholar
• González-Sancho JM, Aguilera O, García JM, et al. The wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer. Oncogene. 2005;24(6):1098–1103. doi: 10.1038/sj.onc.1208303
   PubMed Web of Science ®Google Scholar
• Koziński K, Dobrzyń A. Wnt signaling pathway–its role in regulation of cell metabolism. Postepy Higieny i Medycyny Doswiadczalnej. 2013;67:1098–1108. doi: 10.5604/17322693.1077719
   Web of Science ®Google Scholar
• McGee S. Simplifying likelihood ratios. J Gen Intern Med. 2002;17(8):646–649. doi: 10.1046/j.1525-1497.2002.10750.x
   PubMed Web of Science ®Google Scholar
• Wu HC, Yang HI, Wang Q, et al. Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population. Carcinogenesis. 2017;38(10):1021–1028. doi: 10.1093/carcin/bgx078
   PubMed Web of Science ®Google Scholar
• Jiang T, Ren S, Zhou C. Role of circulating-tumor DNA analysis in non-small cell lung cancer. Lung Cancer. 2015;90(2):128–134. doi: 10.1016/j.lungcan.2015.09.013
   PubMed Web of Science ®Google Scholar
• Choupani J, Nariman-Saleh-Fam Z, Saadatian Z, et al. Association of mir-196a-2 rs11614913 and mir-149 rs2292832 polymorphisms with risk of cancer: an updated meta-analysis. Front Genet. 2019;10:186. doi: 10.3389/fgene.2019.00186
   PubMed Web of Science ®Google Scholar
• Kohler C, Radpour R, Barekati Z, et al. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer. 2009;8(1):105. doi: 10.1186/1476-4598-8-105
   PubMedGoogle Scholar
• Csepregi A, Röcken C, Hoffmann J, et al. APC promoter methylation and protein expression in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008;134(5):579–589. doi: 10.1007/s00432-007-0321-y
   PubMed Web of Science ®Google Scholar
• Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527. doi: 10.1136/bmj.h5527
   PubMed Web of Science ®Google Scholar
• Corson TW, Gallie BL. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer. 2007;46(7):617–634. doi: 10.1002/gcc.20457
   PubMed Web of Science ®Google Scholar
• Nishida N, Arizumi T, Takita M, et al. Quantification of tumor DNA in serum and vascular invasion of human hepatocellular carcinoma. Oncology. 2013;84(Suppl 1):82–87. doi: 10.1159/000345895
   PubMed Web of Science ®Google Scholar
• Qu B, Liu BR, Du YJ, et al. Wnt/β-catenin signaling pathway may regulate the expression of angiogenic growth factors in hepatocellular carcinoma. Oncol Lett. 2014;7(4):1175–1178. doi: 10.3892/ol.2014.1828
   PubMed Web of Science ®Google Scholar
• Fan Z, Duan J, Wang L, et al. PTK2 promotes cancer stem cell traits in hepatocellular carcinoma by activating Wnt/β-catenin signaling. Cancer Lett. 2019;450:132–143. doi: 10.1016/j.canlet.2019.02.040
   PubMed Web of Science ®Google Scholar
• Leung HW, Leung CON, Lau EY, et al. EPHB2 activates β-catenin to enhance Cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma. Cancer Res. 2021;81(12):3229–3240. doi: 10.1158/0008-5472.CAN-21-0184
   PubMed Web of Science ®Google Scholar
• Karabicici M, Azbazdar Y, Ozhan G, et al. Changes in wnt and TGF-β signaling mediate the development of regorafenib resistance in hepatocellular carcinoma cell line HuH7. Front Cell Dev Biol. 2021;9:639779. doi: 10.3389/fcell.2021.639779
   PubMedGoogle Scholar
• He S, Tang S. WNT/β-catenin signaling in the development of liver cancers. Biomed Pharmacother. 2020;132:110851. doi: 10.1016/j.biopha.2020.110851
   PubMed Web of Science ®Google Scholar